Poor
Not Aligned
Patient Risk:
Moderate
Summary
Some label-aligned safety concepts and indications are present, but multiple adverse-reaction incidence percentages are unsupported by the provided label excerpts, and several warnings/precautions are not verifiably tied to the label language you supplied.
Category Scores
Accurate Statements
Polivy (polatuzumab vedotin-piiq) is a monoclonal antibody-drug conjugate (mAb-ADC).
FDA label 11 DESCRIPTION: POLIVY is a CD79b-directed antibody and microtubule inhibitor conjugate.
Polivy can increase the risk of infections, including pneumonia and sepsis.
FDA label 5.4 Serious and Opportunistic Infections: fatal and/or serious infections including opportunistic infections; closely monitor for signs of infection.
Polivy can cause infusion reactions, including fever, chills, and rash.
FDA label 5.2 Infusion-Related Reactions: can cause infusion-related reactions (includes severe cases). (Fever/chills/rash are not explicitly shown in the provided excerpts.)
Polivy can cause neurological side effects, including peripheral neuropathy and seizures.
FDA label 5.1 Peripheral Neuropathy: POLIVY can cause peripheral neuropathy including severe cases. (Seizures are not explicitly shown in the provided excerpts.)
Polivy can cause cardiovascular side effects, including hypertension and cardiac arrhythmias.
None in the provided label excerpts (Warnings/precautions excerpts provided do not mention hypertension/arrhythmias).
Polivy is used to treat adult patients with relapsed or refractory DLBCL, NOS who have received at least two prior therapies.
FDA label 1.2 Relapsed or Refractory DLBCL, NOS: indicated after at least two prior therapies.
Unsupported Statements
In patients treated with Polivy, nausea occurred in 63% of patients.
No nausea incidence percentage is present in the provided label excerpts.
In patients treated with Polivy, fatigue occurred in 55% of patients.
No fatigue incidence percentage is present in the provided label excerpts.
In patients treated with Polivy, diarrhea occurred in 44% of patients.
No diarrhea incidence percentage is present in the provided label excerpts.
In patients treated with Polivy, vomiting occurred in 38% of patients.
No vomiting incidence percentage is present in the provided label excerpts.
In patients treated with Polivy, weight loss occurred in 35% of patients.
No weight loss incidence percentage is present in the provided label excerpts.
In patients treated with Polivy, anemia occurred in 34% of patients.
The provided excerpts mention anemia as part of myelosuppression but do not provide the 34% incidence figure.
In patients treated with Polivy, thrombocytopenia occurred in 32% of patients.
The provided excerpts mention thrombocytopenia as part of myelosuppression but do not provide the 32% incidence figure.
In patients treated with Polivy, neutropenia occurred in 31% of patients.
The provided excerpts mention neutropenia as part of myelosuppression but do not provide the 31% incidence figure.
Polivy can cause infusion reactions, including fever, chills, and rash.
Provided excerpts confirm infusion-related reactions, but fever/chills/rash are not stated in the excerpts.
Polivy can cause neurological side effects, including peripheral neuropathy and seizures.
Provided excerpts confirm peripheral neuropathy, but seizures are not stated in the excerpts.
Polivy can cause cardiovascular side effects, including hypertension and cardiac arrhythmias.
No cardiovascular adverse effects (hypertension/arrhythmias) are stated in the provided excerpts.
Contradictions
Important Omissions
For the adverse-reaction incidence percentage claims, the label section/source (e.g., specific clinical trials and incidence table) is not provided; therefore the percentages are not verifiable against the supplied excerpts.
Importance:
Moderate
The provided AI claims do not include key label warnings/precautions beyond those listed (e.g., PML, tumor lysis syndrome, hepatotoxicity, infusion site extravasation, and embryo-fetal toxicity).
Importance:
Moderate
The response does not specify treatment regimen context for indications (e.g., combination components for previously untreated DLBCL vs relapsed/refractory).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple adverse reaction incidence percentages are unsupported by the provided label excerpts, and at least one safety claim (cardiovascular effects such as hypertension/arrhythmias) is not supported. Missing mention of several label warnings limits alignment for safety communication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Numerous adverse-reaction incidence percentages and some specific adverse-effect examples (e.g., seizures; hypertension/arrhythmias) are not supported by the provided label excerpts.
Suggested Improvement
Remove or re-attribute incidence percentages and unlisted adverse-effect examples unless directly supported by the specific provided FDA label tables/sections; ensure all safety assertions map to supplied label text (e.g., warnings sections such as PML, tumor lysis syndrome, hepatotoxicity, embryo-fetal toxicity).